• Home
  • Articles
  • Global News
  • Interest
  • Health Tips
  • Write for Us
    • Contact Us
      • About
      • Privacy Policy

Browse Tag

immuno-oncology

February 7, 2019
Pharmaceutical News

Pathios Therapeutics and Sygnature Discovery sign a strategic and innovative partnership to develop first in class therapies

Pathios Therapeutics (“Pathios”), an innovative biotech company focused on the development of first in class therapies for autoimmune diseases and immuno-oncology and Sygnature Discovery (“Sygnature”), jointly announce a strategic partnership to accelerate Pathios’ drug discovery and development programmes. As part of the agreement, Pathios

More
Press Release: PMR Projects Global Immuno-Oncology Therapy Market Value to Hit the US $ 1O Bn Mark in 2019 End
October 15, 2019

PMR Projects Global Immuno-Oncology Therapy Market Value to Hit the US $ 1O Bn Mark in 2019 End

The immuno-oncology therapy has shown excellent results in various clinical trials and

Press Release: PMR Projects Global Immuno-Oncology Therapy Market Value to Hit the US $ 1O Bn Mark in 2019 End
Pharmaceutical News

PMR Projects Global Immuno-Oncology Therapy Market Value to Hit the US $ 1O Bn Mark in 2019 End

October 15, 2019

The immuno-oncology therapy has shown excellent results in various clinical trials and in patients being treated with immune-oncology therapy. Immuno-oncology

More
Pharmaceutical News

Pathios Therapeutics and Sygnature Discovery sign a strategic and innovative partnership to develop first in class therapies

February 7, 2019

Pathios Therapeutics (“Pathios”), an innovative biotech company focused on the development of first in class therapies for autoimmune diseases and

More
  • Croda and Botanical Solution Inc. (BSI) partner to fast-track sustainable vaccine adjuvant QS-21 production
  • Liquid Nitrogen Freezers Prove to be Game Changer for Pharma Industry
  • Breye Therapeutics Strengthens Management Team and Board
  • How Healthcare Professionals Benefit From Field Hospitals
  • Sterling Pharma Solutions Granted MIA (IMP) License by MHRA for cGMP Antibody-Drug Conjugate Manufacturing at its Facility in Deeside, UK

© 2010-2022 PharmaMirror.com - All Rights Reserved.

  • Home
  • Articles
  • Global News
  • Interest
  • Health Tips
  • Write for Us
  • Home
  • Articles
  • Global News
  • Interest
  • Health Tips
  • Write for Us
    • Contact Us
      • About
      • Privacy Policy
Go toTop